Search results
Results From The WOW.Com Content Network
PCA3 has been shown to be useful to predict the presence of malignancy in men undergoing repeat prostate biopsy. [9] [10] This means that it could be useful clinically for a patient for whom digital rectal examination and PSA suggest possible prostate cancer, but the first prostate biopsy returns a normal result. This occurs in approximately 60 ...
Prostate cancer antigen 3 is a urine test that detects the overexpression of the PCA3 gene, an indicator of prostate cancer. [32] [46] [47] [44] ConfirmMDx is performed on tissue taken during a prostate biopsy. The test identifies men with clinically significant prostate cancer who would benefit from further testing and treatment.
Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder.Abnormal growth of prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels.
Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), P-30 antigen, is a glycoprotein enzyme encoded in humans by the KLK3 gene.PSA is a member of the kallikrein-related peptidase family and is secreted by the epithelial cells of the prostate gland in men and the paraurethral glands in women.
The LNCaP (Lymph Node Carcinoma of the Prostate) cell line was established from a metastatic lesion of human prostatic adenocarcinoma.The LNCaP cells grow readily in vitro (up to 8 x 10 5 cells/sq cm; doubling time, 60 hr), form clones and are highly resistant to human fibroblast interferon. [1]
Tumor markers may be used for the following purposes: Monitoring the malignancy; When a malignant tumor is found by the presence of a tumor marker, the level of marker found in the body can be monitored to determine the state of the tumor and how it responds to treatment.
EDRN PCA3 Validation Trial and Urinary Reference Set, Sponsor: NIH/Gen-probe, 2009-2012. Co-Investigator: S12-03826: An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT). 2015 [ 2 ]
Carcinoembryonic antigen (CEA) describes a set of highly-related glycoproteins involved in cell adhesion.CEA is normally produced in gastrointestinal tissue during fetal development, but the production stops before birth.